aTyr Pharma to present poster of efzofitimod’s mechanism of action

aTyr Pharma announced that the company will present data for its lead therapeutic candidate, efzofitimod, at the American Thoracic Society 2024 International Conference, which is scheduled to take place May 17 – 22 in San Diego, CA. The poster presents findings demonstrating that by selectively binding neuropilin-2, a cell surface receptor upregulated at active sites of inflammation, most notably on myeloid cells, efzofitimod modulates the differentiation of monocyte-derived macrophages in healthy donors and ILD patients, resulting in a unique phenotype with reduced inflammatory potential. Additionally, the data further validates the discovery of NRP2 as an important new immune target, with higher expression of NRP2 detected on circulating monocytes from ILD patients compared to healthy donors and on macrophages within pulmonary sarcoidosis granulomas and other tissues from chronic inflammatory diseases. These findings suggest that efzofitimod may have broad therapeutic potential in diseases where myeloid cells play a central role in pathology, including ILD.